On March 8, 2021 Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, reported that the Japan Patent Office issued a notice of allowance for a new patent application (number 2017-543802) covering AllocetraTM, the Company’s immunotherapy product candidate (Press release, Enlivex Therapeutics, MAR 8, 2021, View Source [SID1234576197]). Upon issuance, the patent, titled "Combination Immune Therapy and Cytokine Control Therapy for Cancer Treatment", will provide added intellectual property protection in Japan with respect to certain methods, uses and pharmaceutical compositions for AllocetraTM in combination with CAR-T therapies. The company expects that this new patent will be issued in Japan in the second quarter of 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Enlivex is developing AllocetraTM as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as "unmet medical needs", as a stand-alone therapy or in combination with other therapeutic agents.